COMPARE · Data as of August 21, 2026
RMD vs STVN
Verdict: Side-by-side breakdown using the Bull Rankings model. RMD scored 81.0, STVN scored 63.4 — RMD leads.
Compare another set
Different reporting periods. RMD's fundamentals are as of June 2026, but STVN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
RMD
ResMed Inc.
81
$231.52 · $33.4B
fundamentals as of
Score gap
17.6
RMD leads
STVN
Stevanato Group S.p.A.
63.4
$22.60 · $6.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthRMD+9.9%
- Strongest balance sheetRMD0.13
- Highest qualityRMD90 / 100
- Largest discount to fair valueRMD-4%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
RMD
stronger →← stronger
STVN
90
Qualityreturns · margins · balance sheet
52
82
Growthrevenue & earnings expansion
75
72
Valuevaluation vs sector peers
76
RMD is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
RMD
STVN
$1.6bC+
FCF
-$36mF
+9.9%B
Rev
+7.4%B
0.13B+
D/E
0.29B
22.2xB+
P/E
—
1.34B
PEG
0.37A
—
P/S
4.3xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
RMD
STVN
4% below
Price vs fair valuelower is cheaper
—
~5%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-4%
1-yr DCF upside
—
+5%
5-yr DCF upside
—
+18%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
RMD
Why this score
- Raising its dividend
- Durable high returns
STVN
Why this score
- Foreign reporter (EUR)
The companies
RMDResMed Inc.
Why now
Medical Instruments & Supplies · market cap $33.4b. Down 21% from 52-week high of $293.58 — deep drawdown territory. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $245.50 (implying +6% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
STVNStevanato Group S.p.A.
Why now
Medical Instruments & Supplies · market cap $6.2b. 19% off the 52-week high of $28.00. PEG 0.37 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $24.83 (implying +10% upside).
Moat
Higher-variance name — the moat signals on the quantitative card are modest, so the durability case rests on execution (turning current growth into durable earnings power) or an un-monetized asset (IP / network effects / first-mover position) rather than an entrenched competitive position.
Risk
Free cash flow is negative (-$36m) — capital raises or debt issuance likely required; dilution / leverage risk. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where RMD and STVN diverge
On the headline score the gap is 17.6 points in favor of RMD. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityRMD 90.3 · STVN 52.1RMD +38.2
- GrowthRMD 81.6 · STVN 75.4RMD +6.2
- ValueRMD 72.1 · STVN 75.6STVN +3.5
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.